CD36 modulators (Mperia Therapeutics)

N/A

Report date: 2025/06/11 11:28:50

Base Information

Drug NameCD36 modulators (Mperia Therapeutics)
Drug Alias NameMPE-001 (Mperia Therapeutics/ Universite de Montreal)Azapeptide CD36 modulators (University of Montreal)DBG-178YGR-100YGR-212-4 +[6] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionAngiogenesis inhibitorsPlatelet glycoprotein 4 modulators
TargetsPlatelet glycoprotein 4
Therapy Area/IndicationsGeographic AtrophyMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversite De Montreal
China Registration ClassN/A

Develop Information

Active CompaniesMperia Therapeutics Inc
Inactive CompaniesUniversite De MontrealUnivalor
Active IndicationsGeographic Atrophy
Inactive IndicationsMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A